Compare Neurocrine Biosciences Inc (NBIX) vs Teradyne, Inc. (TER) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Teradyne, Inc. — how do they compare? Neurocrine Biosciences Inc trades at $141.09 (market cap $14.60B), while Teradyne, Inc. trades at $408.01 (market cap $64.38B). The key difference: Teradyne, Inc. is far larger — about 4.4× Neurocrine Biosciences Inc's market cap, and Teradyne, Inc. pays a 0.13% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and Teradyne, Inc. for 37 Days on average.
| NBIX | TER | |
|---|---|---|
Market Cap | $14.60B | $64.38B |
Volume | 1,075,694 | 2,394,954 |
Sector | Health | Technology |
52-Week High | $185.50 | $483.84 |
52-Week Low | $123.10 | $132.05 |
Typical Hold Time | 23 Days | 37 Days |
Enterprise Value | $14.61B | $64.12B |
Dividend Yield | — | 0.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, with a bearish technical signal but strong fundamentals including a 20.91% net income margin and consistent earnings beats. Recent news highlights pipeline advancements in Prader-Willi syndrome and executive appointments, while analyst consensus remains strongly bullish with a $204.18 price target.
The outlook is positive based on robust profitability and growth initiatives, though risks include execution of pipeline diversification and potential pricing pressure on key drug Ingrezza. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharma company with a deep pipeline, balanced by near-term technical weakness.
Teradyne (TER) trades at $398.72, down 7.34% over 24 hours, but maintains strong technical support near $399. The company demonstrates robust fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and expanding AI-driven test portfolio through new products like Magnum E2 and Iris 100. Revenue growth is projected to accelerate from $3.19B in 2025 to $4.5B in 2026, with net income margin improving to 25.76%.
Outlook remains positive with 61% analyst buy ratings and $461.50 consensus price target, representing 16% upside. Key risks include semiconductor cycle volatility and competitive pressure from KLAC & COHU. Institutional accumulation continues with recent purchases by Envestnet and Nykredit, supporting bullish sentiment despite insider selling.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Teradyne, Inc.
Teradyne provides testing equipment, including automated test equipment for semiconductors, system testing for hard disk drives, circuit boards, and electronics systems and wireless testing for devices. The firm entered the industrial automation market in 2015, into which it sells collaborative and autonomous robots for factory applications. Teradyne serves numerous end markets and geographies directly and indirectly with its products, but its most significant exposure is to semiconductor testing, which made up 71% of 2021 sales. Teradyne serves vertically integrated, fabless, and foundry chipmakers with its equipment.
Read more on TER →
